Distinct alterations of fecal microbiota refer to the ef fi cacy of adalimumab in crohn s disease

HIGHLIGHTS

• who: August and collaborators from the Taras Shevchenko National University of University of Salento, Italy have published the research: Distinct alterations of fecal microbiota refer to the ef fi cacy of adalimumab in Crohn s disease, in the Journal: Gut microbiota alteration trends during adalimumab therapy Recent evidence have suggested that certain gut microbiota composition and function are specially associated with the clinical and endoscopic responses to IFX, providing potentially predictive biomarkers for IFX treatment decisionmaking (Zhuang et_al, 2020). On account of this, we considered that there may be a window of opportunity allowing microbial of 31 . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.